This is a very smart buy. Even if Lilly's AD products fail, they will be able to use all the scientific expertise they have gained to maximize the use of this product. It also gives them immediate acess to other drug company's trials that are using AV-45/.
Some people think that these scans will be routine to test for Early, asymptomatic AD for every one at say age 40 or 45 for early detction
Market Data 
Markets 
AI
